Medicare Coverage for Chronic Kidney Disease (CKD): 2025 Guide

Chronic kidney disease affects more than 37 million Americans, and Medicare covers a comprehensive range of services to help slow its progression — from free dietitian visits and kidney disease education to landmark new medications that reduce kidney disease progression by 30–40%. Understanding what Medicare covers at each stage, and the critical transition rules when kidney disease reaches end stage, can significantly affect your health outcomes and your finances.

Medicare CKD Coverage: Quick Reference

CKD Stages and What Medicare Covers at Each Stage

Chronic kidney disease is classified into five stages based on estimated glomerular filtration rate (eGFR), which measures how well the kidneys are filtering blood. Medicare covers management throughout all five stages, with certain benefits — like kidney disease education — triggered at specific stages.

Medical Nutrition Therapy (MNT): One of CKD's Most Valuable Free Benefits

Medical Nutrition Therapy is a clinical service provided by a registered dietitian nutritionist (RDN) specifically focused on managing a disease through dietary intervention. For CKD patients, MNT involves individualized dietary counseling on protein restriction, potassium and phosphorus management, sodium and fluid intake, and nutrition strategies to reduce kidney strain and delay progression to ESRD.

Who qualifies for $0 MNT:

• Medicare Part B beneficiaries with CKD stages 3, 4, or 5 who are not on dialysis
• Medicare Part B beneficiaries who have received a kidney transplant
• Beneficiaries with diabetes also qualify for MNT separately under the diabetes benefit

MNT frequency under Medicare:

• First year of benefit: Unlimited visits — as many as are medically necessary and ordered by your physician
• Subsequent years: 2 visits per year; additional visits may be approved if there is a change in your diagnosis or medical condition that requires a new plan of care

How to access MNT: Your physician must provide a written referral to a Medicare-enrolled registered dietitian. The dietitian must be enrolled as a Medicare provider. You do not need to use a hospital-based dietitian — many private practice registered dietitians accept Medicare. Ask your nephrologist for a referral if one has not been offered. Telehealth delivery of MNT is covered under Medicare.

Research consistently shows that CKD patients who receive medical nutrition therapy have slower rates of eGFR decline and longer time to dialysis compared to those who do not. The $0 cost-sharing makes this one of the highest-value interventions available to CKD patients on Medicare.

SGLT2 Inhibitors for CKD: Landmark Coverage

The approval of SGLT2 inhibitors for the treatment of chronic kidney disease independent of diabetes represents one of the most significant advances in nephrology in decades. Medicare Part D covers both currently FDA-approved SGLT2 inhibitors for CKD — though as brand-name medications, costs can be significant before the annual out-of-pocket cap is reached.

Dapagliflozin (Farxiga) — FDA-Approved for CKD in 2021

The FDA approved dapagliflozin (Farxiga, AstraZeneca) for CKD in April 2021 based on the landmark DAPA-CKD trial. That trial enrolled patients with CKD stages 2–4 with elevated urine albumin (proteinuria) and found that dapagliflozin reduced the composite risk of sustained eGFR decline of at least 50%, ESRD, death from kidney failure, or cardiovascular death by 39% relative to placebo — in both diabetic and non-diabetic patients. The trial was stopped early because the benefit was so clear.

Empagliflozin (Jardiance) — FDA-Approved for CKD in 2023

The FDA approved empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) for CKD in July 2023 based on the EMPA-KIDNEY trial, which enrolled a broader population — including patients with eGFR as low as 20 mL/min and patients with little or no proteinuria. The trial showed empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% relative to placebo. This expanded the patient population who may benefit compared to the dapagliflozin trial's enrollment criteria.

Medicare Part D Coverage for CKD SGLT2 Inhibitors

Both Farxiga and Jardiance are covered by Medicare Part D when prescribed for CKD. As brand-name drugs with no generic equivalent available in 2025, they are typically placed on Tier 3 or Tier 4 of most Part D formularies, meaning monthly cost-sharing can range from roughly $45 to over $100 depending on your plan, before the deductible is met and while in the initial coverage phase.

The $2,000 annual out-of-pocket cap (effective January 2025 under the Inflation Reduction Act) provides critical protection for CKD patients on these medications. Once you reach $2,000 in total out-of-pocket Part D costs in a calendar year, you pay $0 for the remainder of the year. For patients who rely on a Tier 3 or Tier 4 SGLT2 inhibitor plus other Part D medications, this cap meaningfully limits financial exposure.

The Medicare Prescription Payment Plan (M3P), also available beginning January 2025, allows beneficiaries to spread their Part D out-of-pocket costs evenly across monthly payments rather than paying large amounts early in the year. This can help manage cash flow for CKD patients paying for brand SGLT2 inhibitors.

Kidney Disease Education: 6 Free Sessions for Stage 4 CKD

Medicare Part B covers up to 6 sessions of kidney disease patient education at $0 cost-sharing for beneficiaries with Stage 4 CKD. This benefit is specifically designed to help patients and their families understand treatment options, prepare for potential dialysis, and make informed decisions about kidney transplantation before reaching ESRD.

What KDE sessions cover:

• How kidneys work and what CKD means for your health
• Overview of dialysis options: hemodialysis (in-center vs. home), peritoneal dialysis (CAPD, APD)
• Kidney transplantation: living donor vs. deceased donor, waitlist process, preemptive transplant
• Conservative (non-dialysis) management for patients who choose that path
• Vascular access planning (for hemodialysis) and the importance of early referral
• Advance care planning and quality-of-life considerations

Access requirements: The sessions must be provided by a CMS-approved kidney disease education program. Your nephrologist must refer you to a Medicare-enrolled KDE provider. Sessions can be individual or in small groups, and may be available via telehealth.

Starting KDE early in Stage 4 — well before reaching Stage 5 — gives patients time to make deliberate, informed decisions about their renal replacement therapy modality, pursue preemptive transplant listing if appropriate, and prepare vascular access (which requires time to mature before use).

Lab Monitoring: What Medicare Covers for CKD

Regular laboratory monitoring is the cornerstone of CKD management. Medicare Part B covers all medically necessary labs when ordered by your physician, subject to the 20% coinsurance after the Part B deductible. Key labs routinely covered for CKD management include:

• Creatinine and eGFR: The primary markers for kidney function and CKD staging. Frequency of monitoring increases as stage advances — typically every 3–6 months in early CKD, every 1–3 months in Stage 4–5.
• Blood urea nitrogen (BUN): A secondary marker of kidney clearance, typically ordered alongside creatinine.
• Basic or comprehensive metabolic panel (BMP/CMP): Includes creatinine, BUN, electrolytes (sodium, potassium, bicarbonate, chloride), glucose, and calcium. Ordered frequently throughout all CKD stages.
• Urine albumin-to-creatinine ratio (UACR): Measures proteinuria — a critical marker for both CKD staging and cardiovascular risk. Elevated UACR is one of the primary indications for ACE inhibitors, ARBs, and SGLT2 inhibitors.
• Phosphorus: Elevated phosphorus (hyperphosphatemia) is a common complication of CKD Stage 3b and beyond, contributing to cardiovascular disease and metabolic bone disease. Monitored regularly and managed with dietary phosphorus restriction, phosphate binders, and in some cases vitamin D analogs.
• Parathyroid hormone (PTH): Secondary hyperparathyroidism is a common complication of advanced CKD. PTH monitoring guides decisions about vitamin D therapy, calcimimetics, and phosphate management.
• Complete blood count (CBC) with differential: CKD causes normocytic anemia through reduced erythropoietin production. CBC guides anemia management including ESA therapy.
• Iron studies (serum iron, TIBC, ferritin): Essential before starting ESA therapy; iron deficiency must be corrected for ESAs to work effectively.
• Bicarbonate / CO2: Metabolic acidosis is common in advanced CKD and accelerates disease progression. Oral sodium bicarbonate supplementation is covered under Part D when prescribed.
• 25-hydroxyvitamin D: Vitamin D deficiency is nearly universal in advanced CKD. Monitoring guides supplementation decisions.

Medicare covers all of the above when ordered with appropriate clinical documentation of medical necessity. Labs drawn at a Medicare-enrolled lab or in your physician's office are covered under Part B; you pay 20% after the deductible.

Anemia Management in CKD: ESA/EPO Coverage

Anemia is one of the most common complications of CKD, resulting from reduced production of erythropoietin (EPO) by the damaged kidneys. Medicare covers erythropoiesis-stimulating agent (ESA) therapy for CKD-related anemia under the following rules:

• Physician-administered ESA (e.g., darbepoetin alfa / Aranesp, epoetin alfa / Procrit): Covered under Medicare Part B when administered in a physician's office or outpatient setting. You pay 20% coinsurance after the Part B deductible. This is the most common billing pathway for pre-dialysis CKD patients.
• Self-administered ESA: If your physician trains you to self-inject at home, the medication is covered under Medicare Part D as a prescription drug, subject to your plan's formulary tier and cost-sharing.

Medicare requires documentation of the hemoglobin level before initiating or continuing ESA therapy. CMS guidelines specify target hemoglobin ranges for ESA use — ESAs are typically initiated when hemoglobin falls below 10 g/dL and target hemoglobin during treatment is generally 10–11.5 g/dL. Iron supplementation (intravenous iron for severe deficiency, oral iron for mild-moderate) must be optimized before or alongside ESA therapy and is covered under Part B (IV iron administered in office) or Part D (oral iron supplements, if prescribed).

ACE Inhibitors and ARBs: First-Line CKD Protection

ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) are the foundational medications for slowing CKD progression, particularly in patients with proteinuria. They reduce intraglomerular pressure and have been shown to reduce the rate of eGFR decline and the risk of progression to ESRD independent of their blood pressure-lowering effects.

Generic ACE inhibitors (lisinopril, ramipril, enalapril, benazepril) and generic ARBs (losartan, valsartan, irbesartan, olmesartan) are covered under Medicare Part D at Tier 1 pricing — typically $0 to $10 per month at preferred pharmacies. These are among the most cost-effective medications in all of medicine, providing substantial kidney-protective benefit at very low cost.

Important monitoring note: ACE inhibitors and ARBs can initially cause a small rise in creatinine (and corresponding drop in eGFR) and an increase in potassium when first started or uptitrated. This is expected and generally does not indicate kidney harm — but requires monitoring. Your physician will typically recheck your BMP 2–4 weeks after starting or adjusting these medications. Medicare Part B covers these monitoring labs.

Home Blood Pressure Monitoring

Hypertension is both a cause and consequence of CKD, and tight blood pressure control is one of the most important interventions for slowing CKD progression. Medicare Part B covers home blood pressure monitors as durable medical equipment (DME) when ordered by a physician as medically necessary. You pay 20% of the Medicare-approved amount after the Part B deductible.

To access DME coverage, your physician must provide a written order documenting medical necessity, and you must obtain the device from a Medicare-enrolled DME supplier. Home blood pressure monitoring in CKD is typically considered medically necessary, as blood pressure targets in CKD are stringent (generally below 130/80 mmHg per current guidelines) and require frequent monitoring to achieve and maintain.

The ESRD Transition: When CKD Becomes End-Stage Renal Disease

When CKD progresses to end-stage renal disease (ESRD) — defined as a sustained eGFR below 15 mL/min requiring renal replacement therapy (dialysis or transplantation) — a separate, comprehensive Medicare ESRD benefit applies. Understanding the timing rules and the employer coverage coordination trap is critical for patients approaching this transition.

ESRD Medicare Eligibility: The 3-Month Waiting Period

For most patients, Medicare ESRD coverage begins on the first day of the fourth month of dialysis — meaning there is effectively a 3-month waiting period after dialysis begins. During those first 3 months, patients without Medicare (or without another insurance policy) face significant out-of-pocket exposure for dialysis sessions, which typically occur 3 times per week in-center.

Exceptions to the waiting period:

• Patients who are already enrolled in Medicare (age 65+ or on Medicare for disability) at the time they begin dialysis do not have a waiting period — Medicare ESRD coverage begins immediately.
• Patients who undergo a kidney transplant before starting regular dialysis have Medicare ESRD coverage begin on the date of transplantation (or the month of hospital admission for transplant), with no waiting period.
• Patients enrolled in a Medicare-approved self-dialysis training program (home hemodialysis or peritoneal dialysis training) may qualify for earlier coverage — beginning the first day of the month the training begins.

The 30-Month Coordination Period: A Critical Trap for Employer-Covered Patients

When a patient who has employer-sponsored health insurance (or is covered under a spouse's employer plan) begins dialysis or receives a kidney transplant and becomes eligible for Medicare ESRD, the employer group health plan (GHP) is required to pay primary for the first 30 months. Medicare acts as the secondary payer during this entire 30-month coordination period.

This creates a critical planning issue:

• Do not drop your employer coverage when you become eligible for Medicare ESRD, unless you have carefully reviewed the financial implications. During the 30-month coordination period, losing employer coverage leaves Medicare as the sole payer, which may be less favorable than the coordinated combination.
• The 30-month clock starts on the earlier of: (a) the first month you are eligible for Medicare ESRD based on your dialysis start date, or (b) the first month of the Medicare waiting period (even before your Medicare ESRD coverage becomes active).
• After the 30-month coordination period ends, Medicare becomes the primary payer and your employer plan becomes secondary (or you may be able to drop it).
• This coordination rule applies regardless of employer size, unlike the standard Medicare secondary payer rules for age-based Medicare (which only apply to employers with 20+ employees).

For detailed ESRD coverage — including dialysis, transplant, immunosuppressive medications, and the specific ESRD Medicare enrollment process — see our full Kidney Disease & ESRD Coverage Guide.

Medicare Advantage and CKD: Special Needs Plans

Medicare Advantage (Part C) plans must cover everything Original Medicare covers, but they may offer additional benefits relevant to CKD patients. Some considerations:

• Chronic Condition Special Needs Plans (C-SNPs): These are Medicare Advantage plans specifically designed for beneficiaries with certain chronic conditions, including CKD and ESRD. C-SNPs for kidney disease may include enhanced care coordination, lower cost-sharing for nephrology visits and labs, and additional benefits like transportation to dialysis. They are available in some — but not all — geographic areas.
• Drug formularies: If you are taking an SGLT2 inhibitor, check your Medicare Advantage plan's formulary tier for Farxiga or Jardiance before enrolling. Formulary placement varies significantly between plans and can affect your annual out-of-pocket costs substantially.
• Network restrictions: If you have an established relationship with a nephrologist or a specific dialysis center, verify that they are in-network for any Medicare Advantage plan you are considering. Disrupting a nephrology relationship mid-treatment can be harmful.
• ESRD enrollment restriction: Historically, patients with ESRD could not enroll in most Medicare Advantage plans. The 21st Century Cures Act changed this starting January 2021 — ESRD patients can now enroll in Medicare Advantage plans, including C-SNPs. If you develop ESRD, you are no longer locked out of Advantage plan enrollment.

What Medicare Does NOT Cover for CKD

• Routine dental care: Advanced CKD significantly increases cardiovascular and infection risk, and poor oral health is linked to systemic inflammation. However, Medicare does not cover routine dental care. Consider standalone dental coverage or a Medicare Advantage plan with dental benefits.
• Over-the-counter supplements: Many CKD patients take supplements such as oral sodium bicarbonate (for acidosis), vitamin D, or iron. When prescribed by a physician, some may be covered under Part D. OTC versions are not covered by Medicare.
• MNT for CKD Stage 1 or 2 without proteinuria: The MNT benefit specifically covers CKD stages 3–5. Early-stage CKD patients may need to pay out-of-pocket for dietitian counseling or access it through a Medicare Advantage plan that offers expanded nutrition benefits.
• Transplant evaluation costs (some): While transplant surgery and hospitalization are covered, some pre-transplant evaluation costs (certain specialized tests, second opinions) may generate cost-sharing.
• Caregiver or home health aide support: Extensive home support for CKD management is not covered unless there is a homebound status and a qualifying skilled nursing need. Home health under Medicare is limited to skilled care, not custodial assistance.

Frequently Asked Questions